Important OptumRx updates to support providers, clinical staff and patients through COVID-19.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 19, 2017 – The FDA announced the discontinuation of Teva’s Zecuity (sumatriptan iontophoretic transdermal system).
Download PDF
Return to publications
